|
|
|
| Clinical Efficacy and Safety of Carvedilol Combined with Pancreatopeptidase Injection in the Treatment of Type 2 Diabetic Nephropathy Complicated with Hypertension |
| LI Qian, SU Hang |
| Department of Nephrology, Xianyang Hospital, Yan 'an University, Xianyang Shaanxi 712000 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy and safety of carvedilol combined with pancreatopeptidase injection in the treatment of type 2 diabetic nephropathy with hypertension. 【Methods】A total of 94 patients with type 2 diabetic nephropathy complicated with hypertension were randomly divided into two groups, with 47 cases in each group. All patients received routine treatment. On this basis, the control group was treated with carvedilol, and the observation group was treated with carvedilol combined with pancreatopeptidase injection for 3 months. Blood glucose, blood pressure, renal function, renal artery hemodynamics, clinical efficacy and adverse reactions were observed before and after treatment in two groups. 【Results】(1)The total effective rate of treatment in the observation group was significantly higher than that in the control group (78.72% vs 59.57%,P<0.05). (2) The blood pressure and glucose of the two groups after treatment were lower than those before treatment (P<0.05). There were no significant differences in FPG, 2hPG, SBP and DBP between the two groups before and after treatment (P>0.05).(3)After treatment, BUN, SCr, GFR, UAER and UAlb decreased in both groups, and the extent of decrease in the observation group was greater than that in the control group (P<0.05).(4)After treatment, RI of the two groups decreased significantly, the peak velocity of renal artery systolic velocity (Vmax)and the end diastolic velocity of renal artery (Vmin) increased significantly; and these increase in the observation group were larger than that those in the control group (P<0.05).(5)There was no significant difference in the incidence of adverse reactions between the two groups (P<0.05). 【Conclusion】Carvedilol combined with pancreatopeptidase injection is more effective in the treatment of type 2 diabetic nephropathy complicated with hypertension. It can significantly reduce blood glucose and blood pressure, improve the renal function and hemodynamics of both kidneys, and is safe and effective.
|
|
Received: 06 August 2019
|
|
|
|
|
|
[1] 储苏平, 傅琼. 厄贝沙坦与厄贝沙坦氢氯噻嗪治疗糖尿病合并高血压的疗效比较[J].中国糖尿病杂志, 2013, 21(7): 622-624.
[2] Zhu D.Pancreatic kininogenase ameliorates renal fibrosis in streptozotocin induced-diabetic nephropathy rat[J].Kidney Blood Press Res,2016,41(1):9-17.
[3] 陈诚,沙雯君,朱近悦,等.木丹颗粒联合ARB类药物对2型糖尿病肾病患者肾脏血流动力学及肾素一血管紧张素醛固酮系统影响[J].现代中西医结合杂志,2018,27(14):1517-1520.
[4] 张怡,包蓓艳,陈其军,等.胰激肽原酶治疗早期糖尿病肾病患者蛋白尿的疗效观察[J].中华全科医学,2014,12(5):753-754.
[5] 李敬,朱保月,李颖,等.卡维地洛治疗高血压合并糖尿病患者心律失常临床疗效与安全性的随机对照试验[J].中国循证医学杂志 2014, 14(2): 152-155.
[6] 彭朝胜, 曹悦鞍, 张文洛, 等. 老年2型糖尿病患者血糖波动与室性心律失常的关系[J].中国老年学杂志, 2011, 4(31): 1423-1424.
[7] 张德龙,殷莉,姜芳,等.卡托普利与吲哒帕胺联合卡维地洛治疗原发性高血压疗效及对动态血压、左室结构、肾功能的影响[J].2017,46(12):1781-1782.
[8] 郭华,董丽.丹参和胰激肽原酶联用对早期糖尿病肾病患者尿蛋白的影响[J].中国微循环,2009,13(5):424-426.
[9] 张飞娟,陈晨,冯淑芝,等.胰激肽原酶对糖尿病肾病患者肾功能及血流动力学的影响[J].山东医药,2016,56(6):73-75.
[10] Tomita H,Sanford RB,Smithies O,et al.The kallikrein kinin system in diabetic nephropathy[J].Kidney Int,2012,81(3):733-744. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(3): 455-457. |
|
|
|
|
2021, Vol. 38 
